Clinical Trials
8 trialsNCT01055067 2021-04-06
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
Daiichi Sankyo
Phase 2 Terminated
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01688973 2019-01-03
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01696955 2018-12-19
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01519414 2018-09-12
Tivantinib in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01395758 2018-04-03
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01575522 2016-03-21
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed